NASDAQ · ARVN
Arvinas, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ARVN: Nov 03, 2026
Arvinas, Inc. Common Stock is expected to report earnings on 11/03/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.8. The reported EPS for the same quarter last year was $-0.48.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.80 | $-0.09 | $-1.20 | 5 |
| Dec 2026 | $-0.85 | $-0.17 | $-1.19 | 5 |
| Mar 2027 | $-1.16 | $-1.15 | $-1.18 | 2 |
| Jun 2027 | $-1.10 | $-0.97 | $-1.23 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · The Motley Fool- Zacks · Oct 19, 9:08 AM EDTCan KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?Kymera Therapeutics advances its targeted protein degradation pipeline, with KT-621 trials in atopic dermatitis and asthma marking key milestones amid competition in the field.
- Zacks · Oct 16, 10:21 AM EDTRoche Gets FDA Approval for Enspryng in Thyroid Eye DiseaseRHHBY wins FDA approval for Enspryng in thyroid eye disease, offering the first and only at-home subcutaneous treatment option for patients.
- Zacks · Oct 16, 10:19 AM EDTKRYS Reports Positive Early Data for KB113 in Gorlin SyndromeKrystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.
- Zacks · Oct 13, 10:27 AM EDTReasons Why Investors Should Consider Betting on Arvinas StockARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeting cancer and neurological disorders offers further growth potential.
- Zacks · Oct 13, 9:47 AM EDTTGTX Stock Rises 60% in 6 Months: Here's What You Should KnowTG Therapeutics shares climb 59.9% in six months on strong Briumvi sales uptake, higher 2026 revenue guidance and studies targeting additional indications.
- Zacks · Oct 13, 9:41 AM EDTMirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver DiseasesMIRM's Livmarli meets the phase III EXPAND study goal, improving cholestatic pruritus and reducing serum bile acids, with an FDA filing planned for 2027.
- RTTNews · Oct 7, 7:37 AM EDTArvinas' ARV-102 Shows Biomarker Changes In Parkinson's Phase 1 Trial(RTTNews) – Arvinas (ARVN) reported new Phase 1 data for ARV-102, an investigational oral PROTAC degrader designed to target and degrade LRRK2 in patients with Parkinson's disease.
- RTTNews · Sep 28, 7:29 AM EDTArvinas Advances ARV-6723 Into Phase 1/2 Trial In Advanced Solid Tumors(RTTNews) – Arvinas Inc. (ARVN) announced that the first participant has been dosed in the Phase 1/2 clinical trial of ARV-6723, the company's first clinical candidate in immuno-oncology.
- Zacks · Sep 18, 12:31 PM EDTGinkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains?Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- Zacks · Sep 3, 11:50 AM EDTCan KT-621 Mark a Turning Point for Kymera Therapeutics?KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.
- The Motley Fool · Aug 11, 2:05 PM EDTArvinas (ARVN) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 6, 12:00 PM EDTArvinas (ARVN) Upgraded to Strong Buy: Here's What You Should KnowArvinas (ARVN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Arvinas, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.